Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in advanced melanoma with HR mutations
NCT03925350Phase 2Unknown
- Sponsor
- California Pacific Medical Center Research Institute
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib in melanoma, sponsored by California Pacific Medical Center Research Institute. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
niraparib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03925350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925350.